Accéder au contenu
Merck

In vitro and in vivo antibacterial activity of Pogostone.

Chinese medical journal (2014-11-29)
Fu Peng, Feng Wan, Liang Xiong, Cheng Peng, Min Dai, Jianping Chen
RÉSUMÉ

Our pervious antibacterial studies on several traditional Chinese medicines have found that Patchouli oil from Pogostemon cablin had significant antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), which has spread worldwide and infected innumerable people. In order to find the more active natural substances in Patchouli oil, one of the major components, Pogostone, was isolated and its antibacterial activity was evaluated in vitro and in vivo in this study. In vitro test, Pogostone was screened for antimicrobial properties against 83 bacteria comprising 35 gram positive and 48 gram negative bacteria strains via the agar double dilution method. In vivo test, specific pathogen free (SPF) strain of both male and female white Kunming mice, weighing 18-22 g, were used to test the protective ability of Pogostone after being injected with the median lethal doses (MLDs) of the tested strains. In vitro test, Pogostone could inhibit both gram negative bacteria (0.098-1 600 µg/ml) and gram positive bacteria (0.098-800 µg/ml). For Corynebacterium xerosis and some Chryseobacterium indologenes, the minimum inhibitory concentration (MIC) values of Pogostone were extremely low (<0.098 µg/ml). It was significant that Pogostone was also active against some drug-resistant bacteria like MRSA. Furthermore, Pogostone showed antibacterial activity in vivo against Escherichia coli (E. coli) and MRSA via intraperitoneal injection. Ninety percent of the mice infected with E. coil could be protected at the concentrations of 50 and 100 mg/kg, and 60% of the mice at 25 mg/kg, while the rate of protection for the mice infected with MRSA was 60% and 50% at doses of 100 and 50 mg/kg, respectively. Pogostone could be developed as a potential antibacterial agent for clinical therapy.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Sigma-Aldrich
Cefotaxime sodium salt, suitable for plant cell culture, BioReagent, powder or crystals
Sigma-Aldrich
6-Mercaptohexanoic acid, 90%
Sigma-Aldrich
Azithromycin
Sigma-Aldrich
Cefotaxime sodium salt, potency: 916-964 μg per mg
USP
Levofloxacin, United States Pharmacopeia (USP) Reference Standard
USP
Azithromycin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Cefepime hydrochloride
USP
Cefepime hydrochloride, United States Pharmacopeia (USP) Reference Standard
Supelco
Levofloxacin, analytical standard
USP
Cefotaxime sodium, United States Pharmacopeia (USP) Reference Standard
Azithromycin, European Pharmacopoeia (EP) Reference Standard
Azithromycin for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Azithromycin Identity, United States Pharmacopeia (USP) Reference Standard
Azithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
Cefotaxime sodium, European Pharmacopoeia (EP) Reference Standard
Cefotaxime for peak identification, European Pharmacopoeia (EP) Reference Standard